TY  - JOUR
AU  - Hernández-Cruz, Blanca
AU  - Rosas, José
AU  - Díaz-Torné, César
AU  - Belzunegui, Joaquín
AU  - García-Vicuña, Rosario
AU  - Inciarte-Mundo, José
AU  - Pons, Ana
AU  - Millán, Ana M
AU  - Jeria-Navarro, Sicylle
AU  - Valero, Jesús A
AU  - García-Castañeda, Noelia
AU  - Valero, Cristina
AU  - Llorente, Irene
AU  - Calvo, Alberto
AU  - Díaz-Cerezo, Silvia
AU  - Núñez, Mercedes
PY  - 2022
DO  - 10.1007/s40744-021-00423-8
SN  - 2198-6576
UR  - http://hdl.handle.net/10668/21843
T2  - Rheumatology and therapy
AB  - Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved to treat rheumatoid arthritis (RA). This study aimed to investigate patients' characteristics, prescription patterns, effectiveness, and treatment persistence in patients receiving...
LA  - en
KW  - Baricitinib
KW  - Effectiveness
KW  - Persistence
KW  - Retrospective observational study
KW  - Rheumatoid arthritis
KW  - Spain
KW  - Treatment patterns
TI  - Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study).
TY  - research article
VL  - 9
ER  -